threatened preterm delivery
Conditions
Interventions
Participants take eicosapentaenoic acid 1800mg per day from the day of confirming cervical shortening to 35w6d of gestation or the day of delivery when the deliery occurs before 35w6d.
Sponsors
The University of Tokyo Hospital
Aiiku hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)Between 24 to 28weeks of gestation, pregnant women with shortened cervix length (< or = 25 mm) or Between 29 to 33weeks of gestation, pregnant women with shortened cervix length (< or = 30 mm) 2)Pregnant woman who is at 20 years old or more.(at the time of informed consent) 3)Patients who were required to provide written informed consent
Exclusion criteria
Exclusion criteria: 1)Patients who was transferred from other hospitals 2)Patients with a past history of conization 3)Patients who underwent cervical cerclage in current pregnancy 4)Premature rupture of the membrane 5)fetal anomalies detected by ultrasonography 6)Prolapsed fetal membranes 7)Chorioamnionitis 8)White blood cell count > or =15,000/mm3 or CRP > or =1.0mg/dl 9)Placenta previa 10)Multiple pregnancy 11)Painful degeneration of myomas during pregnancy 12)Uterine malformations 13)Previous medication of eicosapentaenoic acid 14)Medication with low-dose aspirin 15)Patients judged to be ineligible by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Preterm birth | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)gestational age at delivery 2)Birth weight, Apgar score, pH of umbilical arterial blood 3)Cervical length 4)Maternal adverse event 5)Neonatal adverse event 6)Occurrence of adverse events toward neonates 7)Duration of hospital stays 8)Duration of use of a tocolytic agent (ritodrine hydrochloride preparation, magnesium sulfate preparation) 9)Nutrient intakes | — |
Countries
Japan
Contacts
Public ContactTakeshi Nagamatsu
The University of Tokyo Hospital Obstetrics and Gynecology
Outcome results
None listed